Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate DDI Study with CYP Substrates
NCT03234699Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cenobamate in epilepsy, sponsored by SK Life Science, Inc. Primary endpoints: Area Under the Curve at 7 days and Maximum Plasma Concentration at 7 days. Started Feb 2017; status: completed.
02
Drugs
cenobamate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03234699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234699.